SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) announces that it will present data, in conjunction withEndocyte, Inc., comparing its proprietary single cell CTC analysis to PSMA targeted imaging in mCRPC patients to provide insight into disease heterogeneity and identify potential therapeutic resistance mechanisms.
In the study to be presented,
Epic Sciences has previously published the clinical impact of these markers on standard of care therapeutic response in mCRPC, AR targeted therapies or Taxane chemotherapy. "The discordance of PSMA expression in the active metastatic portion of the tumor burden (CTCs) along with the presence of multiple significant markers of therapeutic resistance demonstrate the degree of heterogeneity often observed in this patient population and the need to characterize these resistance mechanisms subclonally prior to and throughout the course of treatment," said Mark Landers, vice president of translational research at Epic Sciences.
Dr. Alison Armour, chief medical officer at Endocyte, commented, "This biological heterogeneity was a consideration in Endocyte's new strategy to target PSMA expression with 177Lu-PSMA-617 as surrounding PSMA negative cells, within the pathlength of the beta emission, could still be irradiated with a 'bystander effect.'"
About Epic Sciences Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX® AR-V7 Nucleus DetectTM test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego.
Further information is available on the Company's website, www.epicsciences.com. Stay in touch on Linkedin, Twitter @EpicSciences or Facebook.com/EpicSciences.
View original content:http://www.prnewswire.com/news-releases/epic-sciences-to-present-single-cell-psma-analysis-to-provide-insight-into-tumor-heterogeneity-and-links-to-response-with-anti-psma-therapy-300595489.html
SOURCE Epic Sciences, Inc.
Subscribe to our Free Newsletters!
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...View All